Engineered T-cell therapy for advanced melanoma patients
Part of Cancer, Skin clinical trials.
This Phase 1 study tests a lab-made immune cell treatment for advanced melanoma. It aims to see if engineered T-cells can recognize the patient’s tumor and help control the cancer, especially in specific melanoma tissue markers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have melanoma that has spread (metastatic) and can be measured on scans or exams
- You are 18 or older and can sign consent before any study tests
- Your health and daily function are good (ECOG performance status 0–1)
- Your tumor tissue tests positive for both tyrosinase and HLA-A2 (from a biopsy)
- Your heart pumping strength is normal for the study (ejection fraction above 50%)
- You are not currently pregnant or breastfeeding, and you can use effective birth control
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment made from your own immune cells (called tumor-infiltrating lymphocytes). The cells are taken from a tumor sample, multiplied in a lab, and given back to you to help fight the cancer. It's for people with melanoma that has not responded to standard immunotherapy.
This trial tests a new treatment called ADP-TILIL7 for people with advanced melanoma. It uses your own immune cells (T-cells) that are taken from a tumor, multiplied in a lab, and then given back to you to fight the cancer. The goal is to see if this treatment is safe and works better than standard options.
This trial tests a treatment that uses your own immune cells, called tumor-infiltrating lymphocytes (TILs), to fight melanoma. Some participants also get a drug called pembrolizumab. The goal is to see if this approach can shrink tumors.
This trial tests a combination of immunotherapy treatments for advanced melanoma that has not responded to standard therapy. The goal is to use your own immune cells to fight the cancer more effectively.
This trial tests a new way to treat advanced melanoma by taking immune cells from your tumor, enhancing them in the lab to fight better, and giving them back to you. It is for people whose melanoma has spread or cannot be removed, and who have already tried standard treatments.
This early-phase study tests a lab-made T-cell treatment that targets a specific tumor marker (MC2) in melanoma and head and neck cancers. It aims to see if the treatment can safely shrink tumors and control cancer after standard options have run out.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.